New Haven Pharmaceuticals Expands Management Team With Two Senior-Level Appointments

BRANFORD, CT--(Marketwired - October 08, 2014) - New Haven Pharmaceuticals, Inc. (the "Company" or "NHP"), a privately-held specialty pharmaceuticals company, has strengthened its management team with the appointment of two experienced pharmaceutical executives to newly-created positions: Dr. Jeffrey Patrick as Chief Scientific Officer, and Michael Richardson as Chief Business Officer.

"We are pleased to welcome two such well-regarded and experienced professionals to our senior management team at this propitious time," said Patrick Fourteau, Chief Executive Officer. "Jeff's broad product experience, which includes the successful launch of several cardiovascular disease management products, will benefit the NHP team in establishing an efficient and effective branded business for our controlled-release aspirin product, DURLAZA. Michael's complementary and broad range of commercial experience includes multiple product launches and the consummation of numerous business development deals, which will help us execute on the market launch of DURLAZA, assuming FDA approval, and expand our product portfolio moving forward."

Jeff Patrick, Pharm.D., joins NHP from Mallinckrodt Pharmaceuticals (MNK) (formerly Covidien), where he most recently was Global Vice President of Medical Affairs. Dr. Patrick previously held leadership positions in several other major pharmaceutical companies, including, Sanofi, Actelion, and Gilead. Dr. Patrick earned his B.S. and Pharm.D. degrees from the University of Tennessee.

Michael Richardson brings nearly twenty years of experience in pharmaceutical marketing, sales, product planning, business development and licensing to this newly-created position. Mr. Richardson joins NHP from Grünenthal USA, where he served most recently as Head of Commercial Affairs. He held prior leadership roles at Grünenthal, Aton, Cephalon, Johnson & Johnson, and Merck. Mr. Richardson holds a B.A. in Chemistry from West Virginia University and an M.B.A. from the Fuqua School of Business at Duke University.

DURLAZA is an investigational novel aspirin product designed to be slowly released into the bloodstream over 24 hours, a longer period of time as compared with currently-available aspirin products. Aspirin (acetylsalicylic acid) prevents clot formation by inhibiting thromboxane, a naturally-occurring prostaglandin derivative that induces platelet aggregation. NHP submitted a New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") in September 2014 for DURLAZA to reduce the risk of stroke or acute cardiac events in patients who have suffered a prior stroke or acute cardiac event.

About New Haven Pharmaceuticals, Inc.
New Haven Pharmaceuticals Inc. ("NHP") is a specialty pharmaceuticals company developing new prescription drug products that utilize currently marketed drugs or generally recognized as safe ("GRAS") active pharmaceutical ingredients to address therapeutic applications that represent large, underserved market opportunities. NHP is currently developing controlled-release aspirin products including DURLAZA™, a proprietary, once-daily oral 24-hour controlled-release aspirin product; a second-generation combination product incorporating proprietary Yale University technology utilizing zinc salts; and, a proprietary zinc salts product designed to lower stomach acid in patients suffering from gastro-esophageal reflux disease ("GERD").

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.